Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Intel
INTC
5
Disney
DIS
US Stock MarketDetailed Quotes
EXEL Exelixis
- 35.590
- -0.600-1.66%
Close Apr 21 16:00 ET
- 35.590
- 0.0000.00%
Post 20:01 ET
9.81BMarket Cap20.22P/E (TTM)
36.560High35.340Low1.95MVolume36.060Open36.190Pre Close69.71MTurnover0.84%Turnover Ratio20.22P/E (Static)275.58MShares40.02052wk High4.37P/B8.24BFloat Cap20.14052wk Low--Dividend TTM231.61MShs Float50.500Historical High--Div YieldTTM3.37%Amplitude1.260Historical Low35.744Avg Price1Lot Size
Exelixis News
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Guggenheim Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $42
Exelixis (EXEL) Gets a Buy From RBC Capital
Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?
Exelixis Launches Special Equity Award Program
Guggenheim Remains a Buy on Exelixis (EXEL)
Truist Financial Maintains Exelixis(EXEL.US) With Buy Rating
Exelixis' Cabozantinib Approval 'Certainly Positive,' Says Citi
Exelixis Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Kidney cancer treatment is facing a transformation, and Morgan Stanley is bullish on the North American Biotechnology industry.
The current Biotechnology Industry is undergoing significant changes in the treatment of renal cell carcinoma.
Citi Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $45
JMP Securities Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $41
Exelixis Gains Buy Rating From Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market
Exelixis Announces U.S. FDA Approval Of CABOMETYX For Patients With Previously Treated Advanced Neuroendocrine Tumors
Express News | Exelixis Announces U.S. FDA Approval of Cabometyx® (Cabozantinib) for Patients With Previously Treated Advanced Neuroendocrine Tumors
Express News | FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pnet and Epnet
Exelixis To Present Preclinical Data For Four Pipeline Molecules At AACR Annual Meeting 2025
Looking Into Exelixis's Recent Short Interest
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
關稅「拉鋸戰」加劇！政策多變下如何應對？
近期，特朗普對等關稅劇情反轉再反轉，關稅再度上演「拉鋸戰」。特朗普此前宣佈暫緩對等關稅90天，但對中國關稅提高125%。對此中國再次強硬反制，並宣佈自4月12日起對原產於美國的進口商品加徵關稅稅率由84%提高至125%。當地時間4月15日，白宮宣佈中國輸往美國的商品現面臨最高達2
Food流油
Apr 14 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"
Discussing
北水爆買！中國資產能否延續漲勢？
3月17日早盤，地產代理、物業服務及管理等板塊漲幅明顯，貝殼-W早盤漲逾4%，碧桂園服務漲逾9%。政策消息面上，兩部門發文落實專項債支持收地，中房協組織民營房企座談會。中國資產本輪火爆行情還能持續多久？你會如何投資？
年頭旺到年尾
Feb 28 00:09
Review on February 27...